Ionis Pharmaceuticals (IONS) Interest Expenses (2009 - 2026)

Ionis Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 328.43% year-over-year to $17.6 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 46.05% decrease from a year earlier, with the FY2025 full-year figure at $342.2 million, down 69.71% from the prior year.
• Interest Expenses climbed to $17.6 million in Q1 2026 per IONS's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Interest Expenses topped out at $230.0 million in Q3 2025 and bottomed at -$1.7 million in Q4 2025.
• The 5-year median for Interest Expenses is $14.8 million (2024), against an average of $26.0 million.
• Biggest YoY gain for Interest Expenses was 4691.67% in 2025; the steepest drop was 111.17% in 2025.
• Year by year, Interest Expenses stood at $1.7 million in 2022, then surged by 593.13% to $12.0 million in 2023, then advanced by 23.24% to $14.8 million in 2024, then slumped by 111.17% to -$1.7 million in 2025, then soared by 1165.38% to $17.6 million in 2026.
• Per Business Quant, the three latest IONS Interest Expenses figures stand at $17.6 million (Q1 2026), -$1.7 million (Q4 2025), and $230.0 million (Q3 2025).